A major pharmaceutical trade group has filed a lawsuit against the U.S. Food and Drug Administration (FDA) over its decision to end the shortage designations for Mounjaro and Zepbound, two popular drugs used to treat Type 2 diabetes and obesity. The lawsuit, filed on Tuesday by the Pharmaceutical Trade Association (PTA), claims that the FDA’s move was premature and has disrupted supply chains, putting patients at risk.
Background: The Shortage and Controversy
The dispute centers around the drugs Mounjaro (tirzepatide) and Zepbound, which have been in high demand due to their effectiveness in managing Type 2 diabetes and their off-label use for weight loss. Manufactured by Eli Lilly, Mounjaro received FDA approval in 2022 and has since become one of the top prescribed medications in its class. Similarly, Zepbound has grown in popularity for its success in aiding weight loss for patients struggling with obesity.
Both drugs were listed as being in short supply earlier this year, leading the FDA to designate them as “in shortage,” a move that allowed manufacturers to prioritize production and work with regulators to streamline supply. However, as supply levels reportedly began to stabilize, the FDA removed the shortage status, sparking concerns from industry groups and some healthcare professionals.
PTA’s Argument: ‘A Premature Decision’
In the lawsuit, the PTA alleges that the FDA’s decision to lift the shortage designation for Mounjaro and Zepbound was “hasty and unsupported by current market conditions.” The group argues that while the FDA may have seen improvements in supply, this does not reflect the ongoing demand from both diabetic patients and those using the drugs for weight management.
“By removing the shortage designation too soon, the FDA has created a false sense of security regarding the availability of these critical medications,” the PTA said in a statement. “Patients are still facing delays and difficulties in accessing these drugs, and the agency’s actions could exacerbate the situation.”
The PTA claims that ending the shortage designation has disrupted supply chains and created confusion among wholesalers and pharmacies, many of whom had been relying on the FDA’s previous status to prioritize orders. The group is asking the court to reinstate the shortage status and compel the FDA to work more closely with manufacturers to ensure a steady supply of both drugs.
FDA’s Response: Supply Levels Are Sufficient
The FDA has defended its decision, stating that it closely monitored supply data and concluded that Mounjaro and Zepbound were no longer experiencing widespread shortages. In a recent statement, the agency emphasized that it would continue to track the availability of both medications and work with manufacturers to address any emerging issues.
“We understand the concerns of the trade group, but our decision was based on careful analysis of supply and demand metrics,” an FDA spokesperson said. “We remain committed to ensuring that all patients have access to the medications they need.”
The agency also highlighted that it had taken multiple steps earlier this year to mitigate shortages, including expediting reviews of manufacturing changes and encouraging increased production capacity. According to the FDA, those efforts have led to a significant increase in supply, warranting the removal of the shortage status.
Impact on Patients and Providers
The lawsuit has raised questions about how patients and healthcare providers will be affected. With supply levels still recovering, some physicians have reported difficulty obtaining sufficient quantities of the drugs for their patients. This is particularly concerning for those with Type 2 diabetes, for whom Mounjaro is a vital part of their treatment regimen.
“The FDA’s move may have been well-intentioned, but it’s created uncertainty in the market,” said Dr. Emily Sharpe, an endocrinologist in New York City. “If supply chains aren’t fully restored, we could see more disruptions in patient care, which is exactly what we want to avoid.”
Meanwhile, some patients have taken to social media to express frustration over the ongoing challenges in accessing the drugs. Many report long wait times at pharmacies and difficulties finding providers who can ensure a steady supply of the medication.
What’s Next?
The lawsuit is expected to move quickly through the courts, as both the PTA and the FDA have indicated a willingness to resolve the issue swiftly. Legal experts say the case could have broader implications for how the FDA handles future shortages and its relationship with industry groups.
For now, the dispute remains a contentious point between the regulatory agency and the pharmaceutical industry, with patients caught in the middle. If the PTA succeeds in reinstating the shortage designation, it could force the FDA to take a more cautious approach to declaring shortages resolved—something the industry has long pushed for.
The case will be closely watched by stakeholders across the healthcare sector, as its outcome could set a precedent for how drug shortages are managed in the future.